Interpace Biosciences Earnings Drop
Interpace Biosciences (OTC:IDXG), a molecular diagnostics company specializing in thyroid cancer risk assessment and other oncology tests, announced its earnings for the second quarter of fiscal 2025 on August 8, 2025. The headline news: a sharp revenue decline to $9.2 million (GAAP) in the wake of losing insurance reimbursement for its PancraGEN® pancreatic cancer test, partially mitigated by record performance in its thyroid diagnostics segment. Profitability fell versus last year, with gross margin (GAAP) slipping to 57% and the company moving to an operating loss of $0.5 million. Performance missed the prior-year period but highlighted a stabilizing core in thyroid diagnostics. No analyst consensus or external estimate comparison was available for this period.
Interpace Biosciences develops and commercializes molecular diagnostic tests aimed at cancer risk assessment, particularly thyroid and pancreatic conditions. Its key products are ThyGeNEXT®, a next-generation sequencing (NGS) assay for thyroid nodules, and ThyraMIR®v2, a microRNA panel that uses an algorithm to classify thyroid cancer risk. The company previously offered PancraGEN®, a molecular test for pancreatic cancer risk, but this line has now been discontinued due to reimbursement loss. Interpace also offers RespriDX® (lung cancer origin differentiation) and is developing BarreGEN® for Barrett’s Esophagus.
The business is now focused exclusively on the thyroid diagnostics segment, reflecting a strategic shift. Success now primarily depends on growing adoption of thyroid test offerings and improving lab operational efficiency through investments in artificial intelligence (AI) and automation technologies.
Source Fool.com
